Lithuanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

cyclooxygenase/vėžys

Nuoroda įrašoma į mainų sritį
Puslapis 1 nuo 46 rezultatus

Method for inhibiting cyclooxygenase-2 and tumor necrosis factor alpha

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to methods for inhibiting cyclooxygenase-2 (COX-2) and tumor necrosis factor alpha (TNF.alpha.) activities and treating disorders and diseases associated with elevated COX-2 and TNF.alpha. activities. 2. Description
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to methods for treatment or prevention of neoplasia disorders using protein tyrosine kinase inhibitors in combination with cyclooxygenase inhibitors, in particular cyclooxygenase-2 selective inhibitors. 2. State of

Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
FIELD OF THE INVENTION This invention is in the field of the prevention and treatment of neoplasia. More specifically, this invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing and treating neoplasia. BACKGROUND OF THE INVENTION Prostaglandins play a major

Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
FIELD OF THE INVENTION This invention is in the field of the prevention and treatment of neoplasia. More specifically, this invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing and treating neoplasia. BACKGROUND OF THE INVENTION Prostaglandins play a major
In recent years, focus is very much on cancer prevention, in acknowledgement of the fact that surgery mostly does not suffice as the only modality and that most cytotoxic regimens are ineffective against solid tumours. With the choices and results of treatment known today, only effective prevention

Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
FIELD OF THE INVENTION The present invention relates in general to cancer. More specifically, the invention provides methods of predicting disease outcome in gastric cancer patients based on the methylation status of the Cox-2 gene promoter region. SEQUENCE LISTING The present invention contains

Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
FIELD OF THE INVENTION The present invention relates in general to cancer. More specifically, the invention provides methods of predicting disease outcome in gastric cancer patients based on the methylation status of the Cox-2 gene promoter region. SEQUENCE LISTING The present invention contains

Screening assays for cancer chemopreventative agents

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
TECHNICAL AREA OF THE INVENTION The invention relates to the area of cancer chemopreventative agents. More particularly, the invention relates to the area of screening assays for cancer chemopreventative agents. BACKGROUND OF THE INVENTION Because common epithelial cancers have resisted most

Treating cancers associated with overexpression of HER-2/neu

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
TECHNICAL FIELD This invention is directed to treatment of HER-2/neu overexpressing cancers. BACKGROUND OF THE INVENTION The HER-2/neu (erbB-2) gene product is a 185-kDA transmembrane receptor tyrosine kinase that belongs to the family of receptors for epidermal growth factor. It is described in

Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
The invention relates to a combination which comprises (a) a cyclooxygenase-2 inhibitor ("COX-2 inhibitor") and (b) a histone deacetylase Inhibitor ("HDAI") for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of pre-malignant colon lesions or a colon cancer

Medicinal compositions for treating colorectal cancer

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
TECHNICAL FIELD The invention relates to a pharmaceutical composition to be administered to the large intestine for treating a colorectal cancer. BACKGROUND ART In cancer therapy the surgical treatment is the mainstream at present. However, in order to improve the performance of the surgical

Indomethacin analogs for the treatment of castrate-resistant prostate cancer

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
TECHNICAL FIELD The presently disclosed subject matter relates to methods and compositions for inhibiting a biological activity of a human aldo-keto reductase family 1, member C3 (AKR1C3; also known as type 5 17.beta.-hydroxysteroid dehydrogenase) polypeptide. In some embodiments, the compositions

Indomethacin analogs for the treatment of castrate-resistant prostate cancer

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
TECHNICAL FIELD The presently disclosed subject matter relates to methods and compositions for inhibiting a biological activity of a human aldo-keto reductase family 1, member C3 (AKR1C3; also known as type 5 17.beta.-hydroxysteroid dehydrogenase) polypeptide. In some embodiments, the compositions

Indomethacin analogs for the treatment of castrate-resistant prostate cancer

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
TECHNICAL FIELD The presently disclosed subject matter relates to methods and compositions for inhibiting a biological activity of a human aldo-keto reductase family 1, member C3 (AKR1C3; also known as type 5 17.beta.-hydroxysteroid dehydrogenase) polypeptide. In some embodiments, the compositions

1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines and inhibitors of cyclooxygenase-2

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
FIELD OF THE INVENTION The invention relates generally to anti-inflammatory drugs, and more particularly to novel compounds which inhibit the activity of cyclooxygenase-2. BACKGROUND OF THE INVENTION The metabolites of arachidonic acid, such as prostaglandins, lipoxygenases and thromboxane products
Prisijunkite prie mūsų
„Facebook“ puslapio

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

  • Dirba 55 kalbomis
  • Žolelių gydymas, paremtas mokslu
  • Vaistažolių atpažinimas pagal vaizdą
  • Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
  • Skaitykite mokslines publikacijas, susijusias su jūsų paieška
  • Ieškokite vaistinių žolelių pagal jų poveikį
  • Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais

Google Play badgeApp Store badge